Ibrahim Aldoss, MD, on KMT2A-Rearranged Acute Leukemia: New Data on Revumenib Monotherapy

January 12, 2024 By The ASCO Post Staff

Ibrahim Aldoss, MD, of City of Hope National Medical Center, discusses phase II safety and efficacy results from the Augment-101 study. This trial showed that patients with heavily pretreated, relapsed or refractory KMT2-rearranged acute leukemia benefited from monotherapy with the menin-KMT2A inhibitor revumenib, with high overall response rates and undetectable measurable residual disease (Abstract LBA-5).

Related Content